A Study of Patients Receiving Adjuvant Nivolumab Therapy for Melanoma That Has Been Removed
An observational study of melanoma participants who are eligible for and who have initiated treatment with adjuvant nivolumab as part of routine clinical practice.
Melanoma
RFS (relapse free survival), 5 years
DMFS (distant metastasis free survival), 5 years|OS (overall survival), 5 years|Distribution of sociodemographic characteristics in participants initiating nivolumab, 5 years|Distribution of clinical characteristics in participants initiating nivolumab, 5 years|Distribution of treatment patterns in participants initiating nivolumab, 5 years|QOL (quality of life) of patients with resected melanoma receiving adjuvant nivolumab therapy by using the EuroQOL-5D (EQ-5D), The EQ-5D is a standardized 3-level, 5-dimensional multi-attribute utility questionnaire that measures mobility, self-care, usual activities, pain/discomfort and anxiety/depression, where each dimension is rated by individuals as no problems, slight problems, moderate problems, severe problems, and extreme problems., 5 years|The European Organization for Research and Treatment of Cancer (EORTC) QLQ C-30 questionnaire, The EORTC-QLQ-C30 questionnaire is a 30-item instrument that comprises 5 functional scales (physical functioning, cognitive functioning, emotional functioning, social functioning and global quality of life) as well as nine symptom scales (fatigue, pain, nausea/vomiting, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties)., 5 years|Functional Assessment of Cancer Therapy-Melanoma (FACT-M) questionnaires, The FACT-M is a frequently used melanoma specific questionnaire which has been validated to assess HRQOL for patients with all stages of melanoma. Besides general questions on Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, and Functional Well-Being, it also contains specific questions related to melanoma, including a subscale on the melanoma surgery, 5 years|Incidence of AE's, 5 years|Incidence of SAE's, 5 years
Participants receiving adjuvant nivolumab therapy could be enrolled prospectively and retrospectively.